Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiothixene SCHEMBL34305 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL782605 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL718331 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL29391417 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL3715363 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL561321 | 0.99 | MEN1 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL30903897 | 0.98 | MEN1 (0.98) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL40977 | 0.98 | MEN1 (0.98) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL721093 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL8022212 | 0.95 | CYP3A4 (0.91) | CYP3A4LMNADRD3CYP2D6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727831-A2 | CARGO ADD-ON DEVICE | Micro Mobility Labs Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024256840-A2 | CARGO ADD-ON DEVICE | MICRO MOBILITY LABS LTD (GB) | 2024-12-19 | — | — | WO | claimed |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | Avior, Inc. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| WO-2026090296-A1 | MONOCYTES AND MONOCYTIC-MYELOID DERIVED SUPPRESSOR CELLS DIFFERENTIATING INTO ANTI-TUMOR MACROPHAGES UPON MICRORNA MODULATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4727831-A2 | CARGO ADD-ON DEVICE | Micro Mobility Labs Ltd (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-3381450-B1 | BIOCOMPATIBLE FILM WITH VARIABLE CROSS-SECTIONAL PROPERTIES | AQUESTIVE THERAPEUTICS INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260044365-A1 | FRAMEWORK AND PROCESSES FOR ARTIFICIAL INTELLIGENCE GUIDED INTERACTIVE AGENTS | WORKATO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534762-B2 | Treating atopic dermatitis by targeting the WNT pathway | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2025-12-11 | — | — | US | disclosed |
| EP-3773511-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2022-07-06 | — | — | EP | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | Avior, Inc. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11298345-B2 | Compounds that modulates AMPA receptor function | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-04-12 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022036306-A1 | METHODS AND APPARATUSES FOR BIOMOLECULE DELIVERY TO PRIMARY HUMAN HEMATOPOIETIC STEM CELLS USING NANOSTRAWS | NAVAN TECHNOLOGIES, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20220033904-A1 | Treating Atopic Dermatitis by Targeting the WNT Pathway | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375432-A1 | COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION | GRIN1, GRM1, GRIN2A | DRD2 117/4885HTR2A 132/4885CYP3A4 1974/4885 |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | TAS2R42, TAS2R39, TAS2R45 | DRD2 2866/4885HTR2A 972/4885CYP3A4 1879/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | DRD2 911/4885HTR2A 207/4885CYP3A4 2316/4885 |
| US-11298345-B2 | Compounds that modulates AMPA receptor function | GRIN1, GRM1, GRIN2A | DRD2 117/4885HTR2A 127/4885CYP3A4 2111/4885 |
| US-20260044365-A1 | FRAMEWORK AND PROCESSES FOR ARTIFICIAL INTELLIGENCE GUIDED INTERACTIVE AGENTS | INTS6, SET, RAD1 | DRD2 2574/4885HTR2A 4082/4885CYP3A4 318/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | DRD2 595/4885HTR2A 183/4885CYP3A4 381/4885 |
| US-12534762-B2 | Treating atopic dermatitis by targeting the WNT pathway | TMEM109, WNT1, TMEM94 | DRD2 2170/4885HTR2A 753/4885CYP3A4 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.